Share Email Print

Proceedings Paper

Evaluation of a novel photosensitizing drug having antitumor effect for advanced prostate cancer
Author(s): Sachiko Saito; Mizuho Inai; Norihiro Honda; Hisanao Hazama; Yasufumi Kaneda; Kunio Awazu
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Prostate cancer is the second most frequently diagnosed cancer among men worldwide and a novel treatment for the disease is required. Replication-deficient virus particles, hemagglutinating virus of Japan envelope (HVJ-E), has cytotoxicity to cancer cells. To enhance the therapeutic effect of HVJ-E by photodynamic therapy (PDT) as a trigger of HVJ-E’s anti-tumor effect, talaporfin sodium (Laserphyrin) used for PDT was encapsulated into HVJ-E to produce a novel photosensitizing drug, named Laserphyrin ®-HVJ-E, and its therapeutic effect for prostate cancer cells (PC-3) was evaluated. As the results, direct cytotoxicities of HVJ-E and Laserphyrin ®-HVJ-E for PC-3 after an administration time of 48 h were almost the same. Cell survival rates of PC-3, which were irradiated 2 h after administration of Laserphyrin ®-HVJ-E, were about 7.8%. Although further study is needed to find an optimal PDT condition, these results suggest that Laserphyrin ®-HVJ-E is useful for treatment of prostate cancer due to the combination of cytotoxicities of HVJ-E and PDT.

Paper Details

Date Published: 1 August 2017
PDF: 5 pages
Proc. SPIE 10417, Medical Laser Applications and Laser-Tissue Interactions VIII, 1041705 (1 August 2017); doi: 10.1117/12.2286071
Show Author Affiliations
Sachiko Saito, Osaka Univ. (Japan)
Mizuho Inai, Osaka Univ. (Japan)
Norihiro Honda, Osaka Univ. (Japan)
Hisanao Hazama, Osaka Univ. (Japan)
Yasufumi Kaneda, Osaka Univ. (Japan)
Kunio Awazu, Osaka Univ. (Japan)

Published in SPIE Proceedings Vol. 10417:
Medical Laser Applications and Laser-Tissue Interactions VIII
Lothar D. Lilge, Editor(s)

© SPIE. Terms of Use
Back to Top